{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Any+Cancer+Type&page=2",
    "query": {
      "condition": "Any Cancer Type",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Any+Cancer+Type&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T06:21:59.060Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01169753",
      "title": "Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Armodafinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2011-05",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2015-12-08",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01169753"
    },
    {
      "nct_id": "NCT01191385",
      "title": "GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "Any treatment for unresectable HCC as chosen by the physician",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-11",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2017-08-16",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 24,
      "location_summary": "Multiple Locations, Arkansas • Multiple Locations, California • Multiple Locations, Colorado + 21 more",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "Arkansas"
        },
        {
          "city": "Multiple Locations",
          "state": "California"
        },
        {
          "city": "Multiple Locations",
          "state": "Colorado"
        },
        {
          "city": "Multiple Locations",
          "state": "District of Columbia"
        },
        {
          "city": "Multiple Locations",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01191385"
    },
    {
      "nct_id": "NCT01217411",
      "title": "RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Solid Neoplasm",
        "Extensive Stage Lung Small Cell Carcinoma",
        "HER2/Neu Negative",
        "HER2/Neu Positive",
        "Male Breast Carcinoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Recurrent Breast Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Recurrent Lung Small Cell Carcinoma",
        "Recurrent Melanoma",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cognitive Assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "Gamma-Secretase Inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Whole-Brain Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2010-10-01",
      "completion_date": "2011-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01217411"
    },
    {
      "nct_id": "NCT04332653",
      "title": "NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Any Advanced Solid Tumors",
        "Triple Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Microsatellite Stable Colorectal Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "NT-I7",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeoImmuneTech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2020-06-10",
      "completion_date": "2025-01-13",
      "has_results": true,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 8,
      "location_summary": "Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04332653"
    },
    {
      "nct_id": "NCT02722395",
      "title": "Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Liver Cancer",
        "Metastatic Liver Cancer From Any Cancer Site"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2016-08",
      "completion_date": "2017-02-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-06",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722395"
    },
    {
      "nct_id": "NCT07050836",
      "title": "Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioma (Any Grade) in the Brain",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Definity contrast during ultrasound",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 2,
      "start_date": "2025-12-05",
      "completion_date": "2026-01-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07050836"
    },
    {
      "nct_id": "NCT02601950",
      "title": "A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Rhabdoid Tumors (MRT)",
        "Rhabdoid Tumors of the Kidney (RTK)",
        "Atypical Teratoid Rhabdoid Tumors (ATRT)",
        "Selected Tumors With Rhabdoid Features",
        "Synovial Sarcoma",
        "INI1-negative Tumors",
        "Malignant Rhabdoid Tumor of Ovary",
        "Renal Medullary Carcinoma",
        "Epithelioid Sarcoma",
        "Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)",
        "Any Solid Tumor With an EZH2 GOF Mutation"
      ],
      "interventions": [
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Epizyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2015-12-22",
      "completion_date": "2024-02-26",
      "has_results": true,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 14,
      "location_summary": "San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 9 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601950"
    },
    {
      "nct_id": "NCT01181271",
      "title": "Tandem Auto-Allo Transplant for Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse, Large B-Cell, Lymphoma",
        "Lymphoma, Low-Grade",
        "T-Cell Lymphoma",
        "Mantle-Cell Lymphoma",
        "Hodgkin's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Lymphoma, Small Lymphocytic"
      ],
      "interventions": [
        {
          "name": "Busulfan (conditioning for AUTO transplant)",
          "type": "DRUG"
        },
        {
          "name": "Etoposide (conditioning for AUTO transplant)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide (conditioning for AUTO transplant)",
          "type": "DRUG"
        },
        {
          "name": "Mesna (prior to AUTO transplant)",
          "type": "DRUG"
        },
        {
          "name": "autologous (auto) peripheral blood stem cell transplantation",
          "type": "OTHER"
        },
        {
          "name": "Neupogen",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine (conditioning for ALLO Transplant)",
          "type": "DRUG"
        },
        {
          "name": "Busulfan (conditioning for ALLO Transplant)",
          "type": "DRUG"
        },
        {
          "name": "non-myeloablative allogeneic (allo) transplant",
          "type": "OTHER"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 42,
      "start_date": "2010-08",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-09",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01181271"
    },
    {
      "nct_id": "NCT02173171",
      "title": "Registry Study for Talimogene Laherparepvec",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial"
      ],
      "interventions": [
        {
          "name": "Information collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 185,
      "start_date": "2010-04-27",
      "completion_date": "2021-09-23",
      "has_results": false,
      "last_update_posted_date": "2021-09-30",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 26,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Santa Rosa, California + 23 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02173171"
    },
    {
      "nct_id": "NCT04482309",
      "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer",
        "Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 477,
      "start_date": "2020-08-18",
      "completion_date": "2027-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-06-26T06:21:59.060Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Muncie",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04482309"
    }
  ]
}